Key facts
- Notable investors include Transfar Capital, Shanghai Dragon Boat Investment Management, Shanghai Kindly Enterprise Development Group Company, Triwise Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Santo Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Santo Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Santo Therapeutics
Developer of gene therapy platforms focused on enhancing drug safety, production efficiency, and treatment accessibility. The company's technologies include a lentiviral vector delivery system, disease modelling tools and process optimisation frameworks, enabling advanced gene therapy development while reducing costs and expanding patient access.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2020
- Website
- santobiopharma.com/
- Ownership
- Privately Held (backing)
Santo Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Santo Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Santo Therapeutics in its N-PORT filings yet. We sweep new filings monthly.